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Early Studies
The question as to who discovered the Rh blood
group system has been vigorously debated for many
years. In 1939, Levine and Stetson correctly described
the etiology of a case of HDN. They did not give a name
to the causative antibody in the serum of Mary Seno;
had they done so Rh might now have a different name.
In 1940, Landsteiner and Wiener described antibodies
produced in guinea pigs and rabbits that had been
injected with RBCs from rhesus monkeys. The
predominant antibody was subsequently shown
apparently to have the same specificity as the causative
antibody in the case of HDN described by Levine and
Stetson. For the rest of their lives Levine and Wiener
each claimed that he had discovered the Rh system
independently of the other. Different terminologies
were used to describe the first and later discovered but
closely related antigens and both Levine and Wiener
had supporters of their claims.
At one time it was suggested that the system had
been discovered earlier. In 1933,Buchbinder published
results from studies using animal sera. Rosenfield
pointed out that Buchbinder was a graduate student
working in Landsteiner’s laboratory and suggested that
some of the antibodies foreshadowed the specificities
reported by Landsteiner and Wiener in 1940 and 1941.
However, from his reading of the results published by
Buchbinder, this author concluded that all the findings
could be explained by the species differences between
the animal sera and the human test RBCs.
Some early findings about Rh were difficult to
explain. Fisk and Foord reported that while human
cord RBCs could be divided into positive and negative
using human anti-Rh, they all reacted with guinea pig
anti-Rh. Murray and Clark found that human RBCs,
divided into positive and negative with human anti-Rh,
all adsorbed guinea pig anti-Rh. Similarly it was claimed
that both Rh+ and Rh– RBCs stimulated production of
anti-Rh in animals. In 1961, Levine et al. reported that
human and animal anti-Rh have different specificities.
The guinea pig anti-Rh was renamed anti-LW,
supposedly in honor of Landsteiner and Wiener. It
followed, of course, that if the antibodies raised in
guinea pigs and rabbits following immunization with
rhesus monkey RBCs had anti-LW specificity, then
Levine and Stetson had discovered Rh in tests on the
serum of Mary Seno. Wiener, of course, rejected such a
claim and maintained that the sera of the immunized
rabbits and guinea pigs contained both what had been
called human anti-Rh and animal anti-Rh. Anti-LW
closely resembles human anti-Rh because the LW
antigen is more strongly expressed on Rh+ than on Rh–
RBCs from human adults.
The fact that the initial experiments of Landsteiner
and Wiener used RBCs from rhesus monkeys as the
immunizing source led to many workers calling the
subsequently discovered complex polymorphism the
Rhesus blood group system. This author was as guilty
as any and even published a book using that name in its
title. In fact the correct name is the Rh system; the
mistake of calling it the Rhesus system was never made
by Race and Sanger, who did much of the early pioneer
work on the polymorphism, nor by Mollison, who did
much to establish the clinical significance of the
system.
Up to this point the term anti-Rh has been used
and the terms anti-D and anti-Rh0 have been
studiously avoided. This is because two distinct
terminologies for Rh were used early and it is difficult
to interpret one group of workers’ results in the other’s
terminology. As discussed in a later section, the
terminology schism stemmed from different theories
regarding the genetic control of Rh antigen
production. Suffice it here to say that the initial studies
on Rh were done with an antibody named anti-Rh0 by
Wiener and his colleagues and anti-D by Fisher and
Race. Levine and his colleagues elected to use the
name anti-D. For the rest of this review the Fisher-Race
(CDE) terminology will be used (initially Wiener’s Rh-
Hr terms will be listed parenthetically) where names
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exist. For later findings, where no CDE terms have
been applied, the numerical terminology of Rosenfield
et al., or the “local” names applied by the reporting
authors, will be used.
Early Expansion: the First Five Antigens
It was not long after the discovery of anti-D (anti-
Rh0) that it became apparent that the situation is far
more complex than a one-antigen, one-antibody
system. In 1941,Wiener et al.described an antigen now
known as C (rh′). It was noticed that most RBCs that
carry C are D+. In the same year Levine et al.described
c (hr′), an antigen found often on D+ RBCs and almost
always on those that are D–. In 1943, Race et al. and
Wiener and Sonn reported the discovery of an antigen
E (rh″). It was seen that E was often present on D+
RBCs, particularly those that were D+, C–. E was
seldom found on D– RBCs. At this point Fisher
postulated that C and c have an antithetical
relationship that is independent of D and E and that
antithetical partners to D and E would eventually be
recognized. In 1945, Mourant et al. reported discovery
of e (hr″), the anticipated antithetical partner to E. No
verifiable discovery of an antigen antithetical to D was
ever reported and eventually the term d came to be
used simply to indicate the absence of D. It was almost
half a century later that biochemical and genetic
evidence was produced to show that indeed most
often when the D gene is absent there is no allelic gene
to replace it. Indeed d and d truly indicate the absence
of D and D in the overwhelming majority of instances.
Genetic Control
Fisher’s concept of the genes C, c, D, d, E, and e
allowed for the existence of Rh gene complexes such
as Cde, cDE, cde, etc., that might represent three
closely linked genes or three subloci within a single
genetic locus. Wiener on the other hand believed that
a single gene at the Rh locus controlled production of
a single agglutinogen that in turn was made up of a
series of blood factors such as Rh0, rh′, and hr″. The
three-gene and one-gene theories of genetic control of
Rh antigen production were as widely debated as the
claim as to who first discovered Rh. Ironically it was
eventually shown by findings at the biochemical and
molecular genetic levels that Rh antigen production is
encoded by two genes. This situation was brilliantly
forecast by Tippett, who based her theory on serologic
findings well before molecular confirmation was
available. Tippett used the MN system as a model. Just
as genes at the MN locus encode production of one
sialoglycoprotein while those at the Ss locus encode
production of another,Tippett postulated that the RHD
gene encodes production of one polypeptide while
genes at the CcEe locus encode production of another.
Just as in the MN system, it was supposed that crossing
over, mutation, gene conversion, or a combination of
these would lead to production of hybrid Rh
polypeptides, the existence of which would explain
the by-then well-known complexity of Rh. It has been
rare in science that such a forecast has preceded
confirmatory evidence yet has been so accurate.
Many More Rh Antigens
Between 1946 and the present, numerous
additional Rh antigens were discovered. In some
instances the serologic studies that led to recognition
of a new antigen were such that the place of the
antigen within the Rh system was apparent. In other
instances an antigen that had been studied or
described in the literature years earlier was shown by
dint of family studies, by association with a highly
unusual Rh gene complex, or by both to belong within
the system. Table 1 lists the 49 Rh antigens that were
included in the 2004 report of the International Society
for Blood Transfusion Committee on Terminology for
Red Cell Surface Antigens (reference given in table).
Because this paper is a historical chronology, the
antigens are listed in Table 1 in sequence of discovery.
Again it should be stressed that the year of discovery
may not be the year that the antigen was assigned to
the Rh system. As the most extreme example, the
antigen Bea was first described by Davidsohn et al. in
1953. It was not added to the Rh system until 1975
after Race and Sanger had shown that the antigen is
produced by a rare gene that also makes c and e.
Although Table 1 lists the antigens in sequence of
discovery, it is more logical to consider them in groups
in which some of the antigens’ characteristics are the
same.
CW, CX, EW, and Rh26
Biochemical and molecular studies mentioned in a
later section have shown that all Rh antigens are
products of alternate alleles at one of the two Rh loci.
However, such knowledge was not available when
many of the antigens were first described. Accordingly
some of those antigens can be considered historically
in light of what was known at the time of their
discovery. For example, CW and CX were originally
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thought to be the products of alleles at the Cc
sublocus. EW was thought to be the product of an allele
at the Ee locus. Now,of course, it is known that CW and
CX are carried on a polypeptide that can also carry C or
c. Rh26 is included in this section because it presents,
at the serologic level, as a variant form of c.
rhi (Ce), cE, CE, f (ce), Rh41, and Rh42
At the time they were reported, these antigens
were thought to be produced when certain genes at
the Cc and Ee loci or subloci were in cis position (i.e.,
on the same chromosome). For example when C was
at the Cc sublocus and e was at the Ee sublocus,Ce (rhi)
was made. Similarly when the subloci were occupied
by c and E, cE was made. These explanations were
sometimes strained by serologic findings. For example,
while f (ce) was invariably a product of the r gene (i.e.,
c and e in cis) it was also apparently made by a Dc–
gene complex that made no e. Now that it is known
that one polypeptide is encoded by a CcEe gene, the
production of these antigens is somewhat easier to
understand.
Hr0, Hr, Rh29, HrB, Rh39, Nou, Sec, Dav, 
and MAR
In 1951,Race,Sanger,and Selwyn described a blood
sample that carried D but no representation of antigens
in the Cc or Ee series. The phenotype was called D– –.
Other examples of what became known as Rh-deletion
phenotypes were soon found. D– – was joined by
DCW– and Dc–. In 1961,Vos et al. described a sample
that lacked all Rh antigens; the term Rhnull was
eventually applied. In studies on antibodies made by
persons with Rh-deletion and Rhnull phenotypes and by
some other persons with very rare but not fully deleted
phenotypes, it became clear that there are a number of
Rh antigens made by all common Rh genes but not by
the rare genes responsible for the phenotypes
described in this section. The antigens defined by
these antibodies are listed in the heading of this
section. It is now known that in some instances
absence of the antigen is a direct consequence of
absence of one of the two Rh polypeptides encoded by
the D and CcEe genes. In other instances lack of the
antigen represents a point mutation that leads to an
amino acid change in the encoded Rh polypeptide
chain. In many such instances the amino acid
substitution results in the presence of an Rh antigen of
low incidence.
Table 1. Rh antigens listed in sequence of initial discovery*
Year of % incidence in a







Hr0 1950 > 99
f 1953 64
Bea 1953 < 1
Cx 1954 < 1
Ew 1955 < 1
V 1955 < 1
Goa 1958 < 1
G 1958 85
Ce(rhi) 1958 70
Hr 1960 > 99
hrS 1960 98
VS 1960 < 1
cE 1961 30
CE 1961 < 1
CG 1962 70
Dw 1962 < 1
Rh26 1964 80
hrH 1964 < 1
Rh29 1967 > 99
Evans 1968 < 1
Rh32 1971 < 1
Rh33 1971 < 1
Rh35 1971 < 1
HrB 1972 > 99
hrB 1972 98
Tar 1975 < 1
Rh39 1979 > 99
Rh41 1980 70
Rh42 1980 < 1
Crawford 1980 < 1
Nou 1981 > 99
Dav 1982 > 99
Riv 1983 < 1
FPTT 1988 < 1
Sec 1989 > 99
BARC 1989 < 1
JAL 1990 < 1
STEM 1993 < 1
LOCR 1994 < 1
MAR 1994 > 99
JAHK 1995 < 1
DAK 2003 < 1
CENR 2004 < 1
*From the 2004 report of the ISBT Committee on Terminology for Red Cell Surface
Antigens. Vox Sang 2004;87:304-6.
In considering these antigens of very high
incidence it will be mentioned that many of them can
be targets for autoantibody production. In 1963,
Weiner and Vos showed that some autoantibodies
causative of warm autoimmune hemolytic anemia
(WAIHA) reacted with all RBCs except those of the Rh-
deletion and Rhnull phenotypes. Others failed to react
only with Rhnull RBCs. Since that time thousands of
similar autoantibodies have been studied. In most
cases the autoantibodies are causative of WAIHA but
exceptions are seen, i.e., in some hematologically
normal persons and in some with drug-induced
autoantibody formation.
Bea, Goa, DW, Evans, Rh32, Rh33, Rh35, Tar,
Crawford, Riv, FPTT, BARC, JAL, STEM,
LOCR, JAHK, DAK, and CENR
The low-incidence antigens in this section heading
are markers of unusual Rh genes at the D or CcEe loci.
Some, such as Goa and DW, began life as “replacement”
antigens when a portion of the D complex of antigens
was missing. Others, such as Rh32 and Rh33, were
markers of the presence of rare Rh genes, the
relationship being painstakingly demonstrated by
serologic tests. Now, of course, it is clear that a point
mutation that substitutes a different from usual amino
acid in either the D or the CcEe polypeptide can result
in the presence of a low-incidence Rh antigen and,
often, the simultaneous absence of a high-incidence
antigen. Somewhat similarly, when hybrid Rh poly-
peptides are formed, the new sequence of amino acids
at the D to CcEe or CcEe to D polypeptide joining site
can result in a new antigen being present.
V, VS, hrS, hrB, and hrH
These antigens have been separated from the
others because, when discovered, each seemed to have
a serologic relationship to e. As an example, in many
studies VS behaved as a variant of e, while V seemed to
be made by the gene complex that made VS when that
gene also made c. The antigens hrS and hrB were
initially recognized when Shapiro studied the famous
Shabalala and Bastiaan samples. Each of those sera
contained an antibody to a very common antigen, Hr
(sometimes called HrS) and HrB, respectively, and a
separable antibody, anti-hrS and hrB, respectively, with a
specificity similar but not identical to anti-e. The
antigen hrH seemed to have some similar relationship to
V and VS. Now these antigens can be regarded as
variants on the CcEe polypeptide.
G and C G
Before 1958, many workers had been puzzled by
the immune response in some persons with D– RBCs.
When exposed to C–,D+ or C+,D– RBCs,some of these
individuals made apparent anti-CD. In 1958, Allen and
Tippett showed that all genes that make C and almost
all genes that make D make another antigen, which
they named G. The supposed anti-CD mentioned above
actually contained anti-G and, dependent on the
phenotype of the immunizing RBCs, often separable
anti-D, anti-C, or both as well. Allen and Tippett
described the rare phenotype C–, D–, G+(rG); later it
was found that the phenotype D+, G– also exists. It is
now known that a sequence of amino acids common
to the D and C polypeptides represents G.
In 1962, Rosenfield et al. described anti-CG as
defining an antigen made by most genes that make C
but not by those that make D without C. It has been
reported that the phenotypes D–, C–, G+, CG+ and D–,
C–, G+, CG– both exist.
Biochemical and Genetic Breakthroughs
For many years, numerous workers tried to isolate
the Rh antigens or the membrane components that
carry them from RBCs. Although there were a number
of reports of success, none of the methods proved
repeatable. When the initial breakthrough was
achieved the methods devised were applied in
numerous laboratories around the world. As a result,
huge amounts of data were accumulated in a short
time. A veritable explosion of knowledge emerged
from studies in Bristol, Paris, and Baltimore. The Rh
polypeptides once isolated were sequenced, the genes
that encode them were recognized, and much
information was obtained about the structure of the
antigens. Thus many workers regard those early papers
that explain the production and structure of D,C,E,etc.
as the pioneer studies. In fact, all subsequent work at
the biochemical and later at the molecular genetic
levels is based on the initial methods devised to isolate
the Rh-bearing polypeptides from RBCs. It is this
author’s belief that in this respect credit devolves on
two independent groups: Moore and his colleagues in
Scotland, who immunoprecipitated membrane
components using antibodies to D, c, and E, and
Gahmberg in Finland, who used a similar technique to
isolate the D-bearing protein. These papers are often
overlooked when reports are written describing the
fine structures of, and differences between, the D-
bearing and CcEe-bearing polypeptides. With regard to
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giving credit where credit is due, these same workers
receive too little recognition for their discovery of the
Rh-related glycoprotein. Gahmberg suggested that in
the membrane the nonglycosylated D-bearing
polypeptide is associated with a glycoprotein. Moore
and Green isolated the Rh-associated glycoproteins and
showed that the one associated with the D polypeptide
differs from the one associated with the CcEe
polypeptide and that the Rh-associated glycoproteins
also carry ABH determinants. These findings were
reported at a time when isolation and sequence studies
on the nonglycosylated Rh polypeptides were in vogue
and were sometimes ignored or even questioned.
Indeed it was not infrequently assumed that the Rh-
associated glycoprotein and the nonglycosylated Rh
polypeptide complex was an artificial one that formed
during the isolation procedure. Such skepticism was
born of the assumption that Rh could be fully
explained in terms of the nonglycosylated
polypeptides. Now, of course, it is known that in one
form of Rhnull the D and CcEe polypeptide-encoding
genes are normal and that the phenotype represents a
defect in the independently inherited genes that
encode production of the Rh-associated glycoprotein.
In other words, the Rh antigen–bearing polypeptides
are not expressed at the RBC membrane level unless
Rh-glycoprotein–Rh-polypeptide (and possibly Ss-
sialoglycoprotein) complexes form. The genes that
encode production of the nonglycosylated Rh
polypeptides are on chromosome 1, while those that
encode production of the Rh-associated glycoproteins
(that do not carry Rh antigens) are on chromosome 6.
Beyond the scope of this review are findings that show
that at a physiologic level tissue-located Rh-associated
glycoprotein analogs are more important than the RBC
Rh antigen–bearing polypeptides.
Rh Polypeptides
As mentioned several times already, two major
forms of Rh polypeptide exist. One is encoded by one
of the various forms of the RHD gene. This polypeptide
carries whole or partial D, G, and, on occasion, a low-
incidence antigen in lieu of a portion of D. Many of the
variant polypeptides mentioned in this section contain
material similar to that of a D-bearing polypeptide. The
second common Rh polypeptide is encoded by one of
the RHCE genes (RHCe, RHCE, RHcE, RHce are
common varieties). This protein carries C or c (variant
forms can carry both) and E or e and G (if C is made).
Again many variant Rh polypeptides carry material
similar to that encoded by RHCE genes. In addition to
the common Rh polypeptides there are now numerous
recognized variant proteins. These are encoded by
genes that have arisen by gene conversion (rearrange-
ment, crossing over) or point mutation. These variant
polypeptides explain virtually all the previously
inexplicable Rh serology. As mentioned in the previous
section on Bea et al., point mutation that results in
insertion of a different from usual amino acid in the
polypeptide chain, in a different sequence of amino
acids that results when hybrid polypeptides are
encoded, or both are prime sources of Rh antigens of
both high and low incidence. In the white population,
the D– phenotype most often represents total absence
of a D gene. In other populations, a different explana-
tion often obtains.Clearly it is beyond the scope of this
historical chronology (and its author) to describe all
the biochemical and genetic complexities in detail.
Interested readers are referred to an excellent (save
that it does not cite Moore et al. or Gahmberg) recent
review by Westhoff (Transfusion 44:1663-73, 2004).
A Note about References
For the sake of clarity, detailed references to the
early findings described in this review are not given.
All papers mentioned are referenced in Chapter 10 of
Applied Blood Group Serology, 4th ed., 1998. Two key
references not listed there i.e., to the 2004 ISBT
Committee report and the Westhoff review,are given in
a previous section.
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